Tysabri Recall Following Reports of Liver Damage, PML

The Food and Drug Administration (FDA) issued a recall of Tysabri one year after its approval following reports that the drug may cause a rare viral brain infection known as progressive multifocal leukoencephalopathy (PML). After investigating the claims, the FDA reintroduced Tysabri to the market; however, it remains under FDA scrutiny after reports surfaced claiming it causes liver damage.

PML, Liver Damage and Other Tysabri Side Effects

Tysabri is an intravenous medication that was approved to treat multiple sclerosis and Crohn's disease – an inflammatory bowel disease. The drug was initially linked to PML, but garnered additional attention following studies linking it to liver disease.

The FDA has issued a warning to health care professionals and consumers to be on the alert for signs of jaundice, such as yellowed eyes and skin, as well as symptoms of progressive multifocal leukoencephalopathy, which include:

• Coma
• Difficulty speaking
• Loss of vision
• emory loss
• Mental deterioration
• Paralysis
• Seizures
• Trouble with cognition
• Weakness

Patients who demonstrate several of these Tysabri side effects should seek immediate medical attention.

Filing A Tysabri Lawsuit

Treatment of PML and liver damage can cause patients to acquire expensive medical bills, as well as interfere with their professional and social lives. The personal injury attorneys of Aylstock, Witkin, Kreis and Overholtz fight tirelessly to help Tysabri victims obtain compensatory damages to offset their physical, emotional and financial damages. In some instances, the lawyers of AWKO recommend victims join a class action lawsuit, which can potentially award millions of dollars in damages to victims. Contact AWKO today at (888) 255-2956 to determine if you might have a case.